Cost-effectiveness of PCSK9 Inhibitors for Heterozygous FH or ASCVD

Interview with Dhruv S. Kazi, MD, MSc, MS, author of Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease

Episode metadata supplied by the publisher feed · Published Aug 16, 2016

Embed this episode

Attribution link and audio player

NOW PLAYING

Cost-effectiveness of PCSK9 Inhibitors for Heterozygous FH or ASCVD

0:00 3:39

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Healthy Dialogue?

This episode is 3 minutes long.

When was this Healthy Dialogue episode published?

This episode was published on August 16, 2016.

Can I download this Healthy Dialogue episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!